h_da joins ASPIRE

28. March 2023

We proudly announce that the ASPIRE team has a new member: Darmstadt University of Applied Sciences joins the consortium and brings in expertise for AI-based brain image analysis and atlas creation. Together we will establish a platform independent dementia diagnosis support based on arterial spin labeling images.

mTRIAL 3.4. release

21. March 2023

We proudly announce the release of our new mTRIAL version. For the first time it incorporates a webbased comprehensive DICOM image viewer for platform independent and real time access of clinical trial data. Central read workflow planning and execution has been upgraded for even more reliable and efficient review of radiological data. mTRIAL 3.4. – ready to support your next image based clinical trial.

Welcome Yaqueen!

14. March 2023

We are very happy to welcome our new team member Yaqeen Ali. He joined mediri for his PhD as Marie Skłodowska-Curie-Fellow. He has completed his master’s degree in Computer Science at Comsats University Islamabad, Pakistan. Together with 9 other Phd students all over Europe he will work in the BosomShield Project aiming at a CAD system for breast cancer relapse prediction. Yaqeen will develop a prototype for a secure remote solution with web access for patient-individual multi-modal image analysis using cloud computing and federated learning.
Looking very much forward to this exciting project with Universitat Rovira i VirgiliKTH Royal Institute of Technology RadboudumcInstitut d’Investigació Sanitària Pere Virgili – IISPVNalecz Institute of Biocybernetics and Biomedical Engineering Polish Academy of SciencesUniversity of UdineUBFC – Université Bourgogne-Franche-ComtéUniverza v Mariboru and nVision Systems.

Digital Innovator Award 2023

13. March 2023

We proudly announce that mediri has been awarded as Digital Innovator 2023 in the category „medical technology and pharmaceuticals“ by CHIP. In times of digitization, CHIP and data analysis specialist Globis Consulting have studied the innovative power of German companies and institutes in digitization. CHIP is known as one oft the top recommendation brands. 
See the full ranking here. 

aerzteblatt article

07. February 2023

If you have two minutes, take a look at this aerzteblatt article about artificial intelligence that is mentioning mediri and the DeepRAY project.

ASPIRE meeting

31. January 2023

Working visit at Amsterdam UMC: The partners in the ASPIRE project spent two days at Amsterdam UMC to pave the way for the final year. ASPIRE will ease the access to non-invasiv imaging biomarkers in dementia and help to get ASL into the clinics.

mTRIAL Freesurfer

30. January 2023

The easiest way to use FreeSurfer for brain volume measurements? Upload your FLAIR images to mTRIAL and enjoy the magic.
Interested? Don’t hesitate to contact us.


17. January 2023

You want the brain MRIs of your MS patients to be evaluated by the SPM Lesion Segmentation Tool but without installing and adapting any software packages? Or do you need consistent evaluations across multiple centres of a clinical trial? mTRIAL offers Lesion analysis of FLAIR images based on the SPM LST algorithm and produces clear reports. You only need to upload your image data to the mTRIAL platform, pseudonymization is performed on the fly, evaluation and reporting can be done within minutes.
Interested? Don’t hesitate to contact us.

Merry Christmas

20. December 2022

Many thanks to all colleagues, partners and friends for a year full of fruitful discussions, exciting projects and fresh ideas. Enjoy the holidays with your loved ones and have a good start into the new year.

Advancements of ASL

13. December 2022

30 years after the first successful Arterial Spin Labeling (ASL) MR image acquisition to measure cerebral blood flow in rat brain, the early detection of Alzheimer’s using ASL gains enormous importance with the recent publication of the study results for Lecanemab. Now that there is hope for efficient therapies in dementia diseases, it is a good time to review the steps that have been gone since then. Many initiatives aiming at reliable and comparable quantification of brain perfusion measurements are paving the way for broad usage of ASL in clinical studies focusing on Alzheimer‘s and other dementia diseases.